140 related articles for article (PubMed ID: 6872257)
1. Urinary excretion of deuterated metabolites in patients with tyrosinemia type I after oral loading with deuterated L-tyrosine.
Wadman SK; Duran M; Ketting D; Bruinvis L; van Sprang FJ; Berger R; Smit GP; Steinmann B; Leonard JV; Divry P; Farriaux JP; Cartigny B
Clin Chim Acta; 1983 May; 130(2):231-8. PubMed ID: 6872257
[TBL] [Abstract][Full Text] [Related]
2. Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia.
Christensen E; Jacobsen BB; Gregersen N; Hjeds H; Pedersen JB; Brandt NJ; Baekmark UB
Clin Chim Acta; 1981 Nov; 116(3):331-41. PubMed ID: 7296896
[TBL] [Abstract][Full Text] [Related]
3. Identification of 4,6-dioxoheptanoic acid (succinylacetone), 3,5-dioxooctanedioic acid (succinylacetoacetate) and 4-Oxo-6-hydroxyheptanoic acid in the urine from patients with hereditary tyrosinemia.
Lindblad B; Steen G
Biomed Mass Spectrom; 1982 Oct; 9(10):419-24. PubMed ID: 7171740
[TBL] [Abstract][Full Text] [Related]
4. Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia.
Berger R; Smit GP; Stoker-de Vries SA; Duran M; Ketting D; Wadman SK
Clin Chim Acta; 1981 Jul; 114(1):37-44. PubMed ID: 7249373
[TBL] [Abstract][Full Text] [Related]
5. Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts.
Manabe S; Sassa S; Kappas A
J Exp Med; 1985 Sep; 162(3):1060-74. PubMed ID: 3928801
[TBL] [Abstract][Full Text] [Related]
6. Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation.
Tuchman M; Freese DK; Sharp HL; Ramnaraine ML; Ascher N; Bloomer JR
J Pediatr; 1987 Mar; 110(3):399-403. PubMed ID: 3546650
[TBL] [Abstract][Full Text] [Related]
7. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
Lindstedt S; Holme E; Lock EA; Hjalmarson O; Strandvik B
Lancet; 1992 Oct; 340(8823):813-7. PubMed ID: 1383656
[TBL] [Abstract][Full Text] [Related]
8. Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinaemia type 1.
Bain MD; Purkiss P; Jones M; Bingham P; Stacey TE; Chalmers RA
Eur J Pediatr; 1990 Jun; 149(9):637-9. PubMed ID: 2373116
[TBL] [Abstract][Full Text] [Related]
9. On the enzymic defects in hereditary tyrosinemia.
Lindblad B; Lindstedt S; Steen G
Proc Natl Acad Sci U S A; 1977 Oct; 74(10):4641-5. PubMed ID: 270706
[TBL] [Abstract][Full Text] [Related]
10. Hereditary tyrosinemia type I--an overview.
Kvittingen EA
Scand J Clin Lab Invest Suppl; 1986; 184():27-34. PubMed ID: 3296130
[TBL] [Abstract][Full Text] [Related]
11. Metabolic studies on two patients with nonhepatic tyrosinemia using deuterated tyrosine loads.
Faull KF; Gan I; Halpern B; Hammond J; Im S; Cotton RG; Danks DM; Freeman R
Pediatr Res; 1977 May; 11(5):631-7. PubMed ID: 870870
[TBL] [Abstract][Full Text] [Related]
12. Persistent succinylacetone excretion after liver transplantation in a patient with hereditary tyrosinaemia type I.
Tuchman M; Freese DK; Sharp HL; Whitley CB; Ramnaraine ML; Ulstrom RA; Najarian JS; Ascher N; Buist NR; Terry AB
J Inherit Metab Dis; 1985; 8(1):21-4. PubMed ID: 2581063
[TBL] [Abstract][Full Text] [Related]
13. A novel mutation causing mild, atypical fumarylacetoacetase deficiency (Tyrosinemia type I): a case report.
Cassiman D; Zeevaert R; Holme E; Kvittingen EA; Jaeken J
Orphanet J Rare Dis; 2009 Dec; 4():28. PubMed ID: 20003495
[TBL] [Abstract][Full Text] [Related]
14. The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase.
Kvittingen EA; Brodtkorb E
Scand J Clin Lab Invest Suppl; 1986; 184():35-40. PubMed ID: 3473612
[TBL] [Abstract][Full Text] [Related]
15. Determination of urinary succinylacetone by capillary gas chromatography.
Tuchman M; Whitley CB; Ramnaraine ML; Bowers LD; Fregien KD; Krivit W
J Chromatogr Sci; 1984 May; 22(5):211-5. PubMed ID: 6725495
[TBL] [Abstract][Full Text] [Related]
16. Impaired synthesis of taurine in a patient with tyrosinemia type I during the oral L-methionine loading test.
Valík D; Klusácek D; Pintera J
Clin Chim Acta; 1992 Sep; 210(3):227-9. PubMed ID: 1468144
[No Abstract] [Full Text] [Related]
17. Enzyme defect in a case of tyrosinemia type I, acute form.
Furukawa N; Kinugasa A; Seo T; Ishii T; Ota T; Machida Y; Inoue F; Imashuku S; Kusunoki T; Takamatsu T
Pediatr Res; 1984 May; 18(5):463-6. PubMed ID: 6145143
[TBL] [Abstract][Full Text] [Related]
18. On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone.
Fällström SP; Lindblad B; Steen G
Acta Paediatr Scand; 1981; 70(3):315-20. PubMed ID: 7246125
[TBL] [Abstract][Full Text] [Related]
19. Concentrations of succinylacetone after homogentisate and tyrosine loading in healthy individuals with low fumarylacetoacetase activity.
Kvittingen EA; Leonard JV; Pettit BR; King GS
Clin Chim Acta; 1985 Nov; 152(3):271-9. PubMed ID: 4064334
[TBL] [Abstract][Full Text] [Related]
20. Tyrosinemia type III: diagnosis and ten-year follow-up.
Cerone R; Holme E; Schiaffino MC; Caruso U; Maritano L; Romano C
Acta Paediatr; 1997 Sep; 86(9):1013-5. PubMed ID: 9343288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
